OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Rheumatology is 59. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Inflammatory arthritis affects men’s fertility	542
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	409
Bimekizumab effective across the axSpA spectrum	355
No benefit from adding MTX to ustekinumab	328
Targeting articular Mmp13 in OA	288
Low-dose rituximab can go even lower	269
Genome-wide mutagenesis reported in systemic sclerosis	258
Rheumatic diseases on the rise	238
A role for TGFβ and EBV in MIS-C pathogenesis	216
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations	209
New drug formulation reduces bone loss	177
Biological and clinical roles of IL-18 in inflammatory diseases	177
FOXP3 splice variant is associated with autoimmune disease	175
Towards better management of sterile bone inflammation	165
Use of platelet-rich plasma for knee OA not supported by RCT results	163
MIS-C: myths have been debunked, but mysteries remain	149
Ageing stem cells hold the key to age-related bone degeneration	147
Urchin-like nanoparticles for miRNA therapy of OA	144
2021 ACR guideline for JIA reflects changes in practice	136
The 2022 ACR vaccination guideline: a call-to-action	132
The value of comparative efficacy studies in informing rheumatology guidelines	126
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?	117
To choose or not? The value of discrete-choice experiments in rheumatology	109
Appraising the evolving landscape of protease inhibition in osteoarthritis	107
Inflammation across tissues: can shared cell biology help design smarter trials?	104

Down syndrome: insights into autoimmune mechanisms	104
Which NSAIDs are best for OA treatment?	101
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	99
Co-trimoxazole reduces mortality in anti-MDA5-DM	98
Low-dose glucocorticoids benefit seniors with RA	97
S100A4 inhibition targets fibrosis in SSc	95
Calprotectin tracks tocilizumab-treated RA	92
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?	85
Wnt-induced IGF1 drives OA	85
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	85
Author Correction: Proposals for the rheumatological use of JAK inhibitors	84
Guiding ILD management in systemic autoimmune rheumatic diseases	83
A direct link between SARS-CoV-2 and bone loss	82
Rheumatology in the digital health era: status quo and quo vadis?	80
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	78
Rheumatic diseases and metabolism: where centre and periphery meet	77
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis	76
Low back pain is a growing concern	76
sCD13 role in arthritis mediated via bradykinin receptor	75
Fumarate drives interferon release in systemic sclerosis monocytes	75
Antibiotics keep rheumatic heart disease at bay	72
Targeting the IVD clock to halt degeneration	71
Erosive cargo from synovial fibroblasts	70
Which DMARD for ICI-associated arthritis?	69
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus	67
ERAP1 and the return of the UPR in ankylosing spondylitis	65
Macrophage-coated nanocarriers for gouty arthritis	65
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	64
Insights into IVDD pathogenesis in 2024	63
PGE2 receptor antagonist has potential to treat osteoarthritis	62
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	62
A path towards personalized medicine for autoinflammatory and related diseases	62
CAR T cells induce drug-free SLE remission	61
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach	60